View of PHARMACOLOGICAL EVALUATION OF A NOVEL BRD4-TARGETING PROTAC TO OVERCOME CISPLATIN RESISTANCE IN TRIPLE-NEGATIVE BREAST CANCER CELLS | Frontier in Medical and Health Research

Frontier in Medical & Health Research

← PHARMACOLOGICAL EVALUATION OF A NOVEL BRD4-TARGETING PROTAC TO OVERCOME CISPLATIN RESISTANCE IN TRIPLE-NEGATIVE BREAST CANCER CELLS